WEBVTT

1
00:00:02.200 --> 00:00:07.765
SS-31 takes peptide science inside the
mitochondrion,

2
00:00:07.914 --> 00:00:11.632
where a membrane's architecture helps cells produce
energy.

3
00:00:11.799 --> 00:00:18.433
Also called elamipretide, this four-amino-acid
molecule belongs to the Szeto-Schiller family.

4
00:00:18.575 --> 00:00:24.690
Hazel Szeto at Cornell in New York and Peter
Schiller in Montreal helped develop the peptides.

5
00:00:24.911 --> 00:00:30.016
A landmark paper appeared in 2004: more than twenty
years of published research.

6
00:00:30.234 --> 00:00:35.471
Its partner is cardiolipin, a lipid in the inner
mitochondrial membrane.

7
00:00:35.609 --> 00:00:41.238
This membrane folds into cristae, supporting
electron transport and production of ATP,

8
00:00:41.415 --> 00:00:43.095
the cell's energy currency.

9
00:00:43.242 --> 00:00:48.776
Laboratory studies found that SS-31 interacts with
cardiolipin and supports

10
00:00:48.776 --> 00:00:51.019
mitochondrial energy processes.

11
00:00:51.220 --> 00:00:56.740
A small randomized study in older adults reported
improved muscle mitochondrial energy

12
00:00:56.740 --> 00:00:59.208
production after one infusion.

13
00:00:59.438 --> 00:01:03.166
This did not establish longer life or lasting
performance benefits.

14
00:01:03.397 --> 00:01:08.987
In September 2025, the FDA granted accelerated
approval to Forzinity,

15
00:01:09.192 --> 00:01:14.566
an elamipretide medicine, to improve muscle
strength in adults and children with

16
00:01:14.566 --> 00:01:17.843
Barth syndrome weighing at least thirty kilograms.

17
00:01:18.048 --> 00:01:21.889
This rare genetic condition affects mitochondrial
function.

18
00:01:22.180 --> 00:01:27.167
Approval drew on knee-extensor strength
improvements during an open-label extension.

19
00:01:27.410 --> 00:01:33.298
The randomized trial did not show superiority on
its walking and fatigue primary endpoints.

20
00:01:33.538 --> 00:01:35.699
A confirmatory trial is required.

21
00:01:35.869 --> 00:01:41.163
Risks include injection-site reactions and serious
allergic reactions.

22
00:01:41.351 --> 00:01:46.973
This specific approval does not cover general
anti-aging use or every product sold

23
00:01:46.973 --> 00:01:48.550
as SS-31.

24
00:01:48.785 --> 00:01:53.700
From molecular design to a rare-disease medicine,
its story shows why

25
00:01:53.967 --> 00:01:55.943
mitochondrial membranes matter.

26
00:01:56.283 --> 00:01:58.004
World Peptide Foundation.

27
00:01:58.236 --> 00:01:59.701
Peptides in 2.

28
00:01:59.858 --> 00:02:01.558
Every experience matters.
